Physician profile
Wasique A Narvel
NPI 1578501615
$5,411.53
in general payments reported to CMS, 2019-2025
41 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $485 · 2021: $815 · 2022: $829 · 2023: $720 · 2024: $792 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $944.51 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $880.45 | 2019-2025 | |
| Novo Nordisk INC | $551.60 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $419.99 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.96 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $206.85 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $205.48 | 2022-2025 | |
| Astellas Pharma US INC | $200.44 | 2019-2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $151.47 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $127.97 | 2022 | |
| Philips North America LLC | $124.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $92.84 | 2019-2023 | Steglatro |
| Amgen INC. | $82.70 | 2024-2025 | Evenity, Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $78.48 | 2019-2024 | Trintellix |
| Evoke Pharma, INC. | $73.42 | 2021-2025 | Gimoti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasique Narvel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.